{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-001349","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.570341+00:00","generated_at":"2026-06-06T08:39:35.901203+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"USPTO allows patent covering levosimendan use in PH-HFpEF through 2040","bullets":["USPTO Notice of Allowance for patent covering oral (TNX-103), IV, subcutaneous levosimendan, active metabolites, and drug combos for PH-HFpEF.","Once granted, patent provides IP protection until Dec 2040, may qualify for patent term extension beyond 2040.","Third patent granted to Tenax since March 2023 protecting levosimendan for PH-HFpEF.","Phase 3 LEVEL study (NCT05983250) ongoing: 152 patients randomized, primary endpoint 6-minute walk distance at Week 12."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-001349","json":"https://secwatch.observer/filing/0001654954-24-001349.json","markdown":"https://secwatch.observer/filing/0001654954-24-001349.md","text":"https://secwatch.observer/filing/0001654954-24-001349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424001349/0001654954-24-001349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424001349/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:39:35.901203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}